Mechanistically, through in vitro and in silico studies, we verified that Hexarelin targets MDM2, subsequently reducing p53 levels and inhibiting the transcriptional promotion of apoptotic cells, thereby safeguarding against apoptosis in I/R-induced AKI (Fig. 7). This evidence concerns the gene TP53 and acute kidney injury.